Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

SIGA vs COLL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

COLL Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)

COLL Overall Winner 6-Pillar Tally: SIGA 1 – 5 COLL Matrix Metrics: SIGA 2 – 8 COLL

As of Nov 20, 2026, Collegium Pharmaceutical, Inc. (COLL) is the stronger overall head-to-head candidate over SIGA Technologies Inc. (SIGA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SIGA carries a Unified Composite Score of 46.2/100 (HOLD) at $2.40 (2.3x Forward P/E, -14.2% operating margin), whereas COLL carries 31.5/100 (SELL) at $24.72 (3.5x Forward P/E, 22.9% operating margin).

  • Composite vs. Pillar Nuance: While SIGA currently prints a higher short-term Unified Composite Score (46.2/100 HOLD vs. COLL 31.5/100 SELL), COLL captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (22.9% vs. -14.2% operating margin) and revenue trajectory (+3.3% vs. -49.7% YoY).
  • Technical & Structure Timing Caution: SIGA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.0); meanwhile COLL is in a Breakdown options structure phase (RSI 53.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SIGA vs COLL
SIGA NASDAQ
SIGA Technologies Inc.
Pharmaceutical Preparations
$2.40
-9.43% 1D
Market Cap $188.3M
TTM Revenue $52M
Forward P/E 2.3x
Beta / 30D Vol 0.90β · 74% Vol
Unified Composite Score
46.2 / 100 HOLD
Tech 33.0 Fund 53.0 Flow 68.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -1.2%), weak momentum, RSI 31
RSI-14: 31.0 · SMA20: $2.99 · SMA50: $3.13
COLL NASDAQ Head-to-Head Winner
Collegium Pharmaceutical, Inc. Common Stock
Pharmaceutical Preparations
$24.72
-1.94% 1D
Market Cap $783.4M
TTM Revenue $815M
Forward P/E 3.5x
Beta / 30D Vol 0.10β · 34% Vol
Unified Composite Score
31.5 / 100 SELL
Tech 35.0 Fund 41.0 Flow 65.0 Mom 32.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 53.8 · SMA20: $24.44 · SMA50: $23.25

6-Pillar Scorecard Institutional Category Breakdown (SIGA 1 – 5 COLL)

Columns: Metric · SIGA · COLL
1. Valuation Multiples SIGA
Forward P/E 2.3x 3.5x
Trailing P/E N/M 23.1x
PEG Ratio 3.37x 0.76x
EV / Revenue 1.4x 2.1x
2. Growth & Scale COLL
Revenue Growth (YoY) -49.7% +3.3%
Earnings Growth (YoY) -65.3% -29.0%
TTM Revenue (USD) $52M $815M
Market Cap $188.3M $783.4M
3. Profitability & Quality COLL
Gross Margin 23.4% 89.4%
Operating Margin -14.2% 22.9%
Net Profit Margin 1.3% 4.7%
Return on Equity (ROE) 0.4% 13.4%
4. Balance Sheet & Cash Flow COLL
Cash Generation (TTM) -$12M $336M
Cash Flow Margin -22.1% 41.3%
Net Cash / Leverage $116M Net Cash $942M Net Debt (3.67x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning COLL
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 94.8% (6th %ile) 93.0% (20th %ile)
Put/Call OI Skew 0.50x (Call-Skewed) 0.14x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat COLL
OpEx & R&D Intensity 37.6% of Rev ($20M) 66.5% of Rev ($542M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SIGA (2) vs COLL (8)
Institutional Metric SIGA COLL Criterion Row Edge
Market Capitalization
Scale
$188.3M $783.4M Larger Scale COLL
Trailing P/E Ratio
Valuation
N/M 23.1x Lower Multiple COLL
Forward P/E Ratio
Valuation
2.3x 3.5x Lower Multiple SIGA
Revenue Growth (YoY)
Growth
-49.7% +3.3% Higher Growth COLL
Operating Margin (TTM)
Profitability
-14.2% 22.9% Higher Margin COLL
Net Profit Margin
Profitability
1.3% 4.7% Higher Margin COLL
Return on Equity (ROE)
Capital Efficiency
0.4% 13.4% Higher ROE COLL
52-Week Range Position
Momentum
2% ($2–$7) 11% ($21–$51) Stronger Trend COLL
Beta / 30D Volatility
Risk Regime
0.90β · 74% Vol 0.10β · 34% Vol Lower Realized Risk COLL
Unified Institutional Score
Composite Signal
46.2 / 100 (HOLD) 31.5 / 100 (SELL) Higher Composite SIGA
Trailing 12M Revenue (USD)
Operating Scale
$52M $815M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
23.4% 89.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
3.37x PEG · 1.4x EV/Rev 0.76x PEG · 2.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$12M ($116M Net Cash) $336M ($942M Net Debt (3.67x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon COLL +29.0 pp
SIGA: -23.81% · COLL: +5.19%
3M Horizon COLL +8.75 pp
SIGA: -18.37% · COLL: -9.62%
6M Horizon COLL +21.28 pp
SIGA: -48.72% · COLL: -27.44%
1Y Horizon COLL +14.98 pp
SIGA: -59.39% · COLL: -44.41%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SIGA Revenue COLL Revenue SIGA Op. Margin COLL Op. Margin Margin Leader
FY2018 $480M $280M 74.4% -7.4% SIGA
FY2019 $30M $300M -8.7% -8.0% COLL
FY2020 $120M $310M 67.6% 18.1% SIGA
FY2021 $130M $280M 66.7% 6.4% SIGA
FY2022 $110M $460M 38.5% 7.2% SIGA
FY2023 $140M $570M 59.8% 29.5% SIGA
FY2024 $140M $630M 50.4% 26.9% SIGA
FY2025 $90M $780M 25.1% 23.0% SIGA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SIGA BREAKDOWN
34d in phase · OBV DISTRIBUTION
Current IV 94.8%
IV Percentile 6th %ile
Put/Call OI Skew 0.50x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact SIGA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
COLL BREAKDOWN
137d in phase · OBV ACCUMULATION
Current IV 93.0%
IV Percentile 20th %ile
Put/Call OI Skew 0.14x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact COLL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SIGA Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $188.3M market capitalization and -14.2% operating margin.
OpEx & R&D Reinvestment 37.6% of Rev ($20M)
90D Engineering Disclosures 0 Published
COLL Moat Profile Scale & Operating Efficiency Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $783.4M market capitalization and 22.9% operating margin.
OpEx & R&D Reinvestment 66.5% of Rev ($542M)
90D Engineering Disclosures 0 Published

Investor FAQ SIGA vs COLL Key Questions & Quantitative Answers

As of Nov 20, 2026, Collegium Pharmaceutical, Inc. (COLL) is the stronger overall head-to-head candidate over SIGA Technologies Inc. (SIGA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SIGA carries a Unified Composite Score of 46.2/100 (HOLD) at $2.40 (2.3x Forward P/E, -14.2% operating margin), whereas COLL carries 31.5/100 (SELL) at $24.72 (3.5x Forward P/E, 22.9% operating margin). Composite vs. Pillar Nuance: While SIGA currently prints a higher short-term Unified Composite Score (46.2/100 HOLD vs. COLL 31.5/100 SELL), COLL captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (22.9% vs. -14.2% operating margin) and revenue trajectory (+3.3% vs. -49.7% YoY). Technical & Structure Timing Caution: SIGA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.0); meanwhile COLL is in a Breakdown options structure phase (RSI 53.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

COLL leads the Growth & Scale pillar: SIGA posts -49.7% YoY revenue growth and -65.3% YoY earnings growth on $52M TTM revenue (23.4% gross margin, -14.2% operating margin), compared with COLL at +3.3% YoY revenue growth and -29.0% YoY earnings growth on $815M TTM revenue (89.4% gross margin, 22.9% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), SIGA cumulative revenue shifted -81.2% while COLL shifted +178.6%. In operating R&D and SG&A reinvestment, SIGA deploys 37.6% of Rev ($20M) (0 90-day corporate R&D disclosures) versus 66.5% of Rev ($542M) (0 disclosures) for COLL.

SIGA screens cheaper on headline valuation multiples. SIGA trades at 2.3x Forward P/E, N/M Trailing P/E, 3.37x PEG, and 1.4x EV/Revenue (-22.1% FCF margin), whereas COLL trades at 3.5x Forward P/E, 23.1x Trailing P/E, 0.76x PEG, and 2.1x EV/Revenue (41.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SIGA (0.4% ROE) versus COLL (13.4% ROE) capital efficiency.

In options market volatility and institutional positioning, SIGA carries 94.8% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.50x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.90β · 74% Vol realized risk). By comparison, COLL carries 93.0% implied volatility (20th %ile, Compressed (<25th %ile)), a 0.14x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.10β · 34% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.